Emerging biotechnologies: full report - Nuffield Council on Bioethics

More documents

Recommendations

Info

E m e r g i n g b i o t e c h n o l o g i e s Appendix 3: The Working Party Professor Michael Moran (Chair) Michael Moran is Professor Emeritus of Government at the University of Manchester. His main interests lie in regulation, especially economic regulation. His publications include Governing the Health Care State (1999), The British regulatory state (2007) and After the Great Complacence: financial crisis and the politics of reform (2011). Dr Jane Calvert Jane Calvert is Reader in Science, Technology and Innovation Studies at the ESRC Innogen Centre. Her broad area of research is the sociology of the life sciences. She is currently studying the emergence and development of systems biology and synthetic biology. She is particularly interested in the role of social scientists in new scientific fields, the differences between biology and engineering, intellectual property and open source, and design and aesthetics in synthetic biology. Mr Trevor Cook Trevor Cook is a partner in the international law firm Bird & Bird LLP. He specialises in patent and other intellectual property litigation and advice and life sciences administrative law. In addition to numerous articles and several co-authored publications, he has written the following books – A User’s Guide to Patents (2011), EU intellectual property law (2010), Pharmaceuticals, biotechnology and the law (2009), A European perspective as to the extent to which experimental use, and certain other, defences to patent infringement, apply to differing types of research (2006) and The protection of regulatory data in the pharmaceutical and other sectors (2000). Professor David Edgerton David Edgerton is Hans Rausing Professor at Imperial College London. He is the Founding Director of its Centre for the History of Science, Technology and Medicine. His most recent books are The shock of the old: technology and global history since 1900 (Profile 2007) and Britain's war machine: weapons resources and experts in the Second World War (Allen Lane/Penguin, 2011). Professor Ray Hill Ray Hill was Head of Licensing and External Research for Europe at Merck, Sharp and Dohme until his retirement in May 2008. He is a pharmacologist with a special interest in pain and headache research and is a Visiting Professor at Imperial College London and Bristol, Surrey and Strathclyde Universities. He is a non-executive Director of several biotech companies and Honorary Biomedical Business Development Advisor at Imperial College London. He is President Emeritus of the British Pharmacological Society. Professor Søren Holm Søren Holm is Professor of Bioethics at the University of Manchester and part-time Professor of Medical Ethics at the University of Oslo, Norway. He is a medical doctor and philosopher and a former member of the Danish <strong>Council</strong> of Ethics. He is the former President of the European Society for Philosophy of Medicine and Health Care and former Editor in Chief of the Journal of Medical Ethics. He currently edits the journal Clinical Ethics. Professor Richard A.L. Jones Richard Jones is Pro-Vice-Chancellor for Research and Innovation at the University of Sheffield, is an experimental physicist whose own research concentrates on the properties of macromolecules at surfaces and interfaces. In his work in nanotechnology he is interested in learning from the principles used by cell biology to create synthetic, functional nanodevices. Professor Jones has also developed 186
E m e r g i n g b i o t e c h n o l o g i e s a more general interest in nanotechnology and its potential impact on society, and has been extensively involved in public engagement around nanotechnology. Professor Eli Keshavarz-Moore Eli Keshavarz-Moore is Professor of Bioprocess Science and Enterprise at University College London. Her research interest is in the bioprocessing of complex macromolecules with therapeutic promise including fusion proteins, antibody fragments (monoclonal and polyclonal), artificial chromosomes and phages; and cells including microbial, mammalian and fungal systems as well as transgenic materials. She is one of the Principal Investigators in the Innovative Manufacturing Research Centre in Bioprocessing. Since 2000, Professor Keshavarz-Moore has led the development and implementation of innovative enterprise training and commercialisation of research opportunities at the bioprocessing/life sciences interface including a leadership programme for Senior Executives in the Bioscience industries. Professor Noel Sharkey Noel Sharkey is Professor of Artificial Intelligence and Robotics and Professor of Public Engagement at the University of Sheffield (Department of Computer Science). He has moved freely across academic disciplines, lecturing in engineering, philosophy, psychology, cognitive science, linguistics, artificial intelligence, computer science and robotics as well as lecturing extensively to the public, policy makers and the military. Noel's core research interest is now in the ethical application of robotics and AI in areas such as military, child care, elder care, policing, telepresence, transport and medicine. He is currently a Leverhulme Research Fellow for an ethical and technical appraisal of Robots on the Battlefield. Professor Andrew Stirling Andy Stirling is Professor of Science and Technology Policy and Research Director at SPRU (Science and Technology Policy Research) at the University of Sussex. He has a background in natural and social science, working formerly as an archaeologist, then a disarmament and environment activist. For 20 years, he has been an interdisciplinary researcher and policy adviser, focusing on challenges in the governance of science, technology and innovation. He has published widely on these issues and served on several public advisory bodies in the UK and EU. A P P E N D I X 3 : T H E W O R K I N G P A R T Y Professor Patrick Sturgis Patrick Sturgis is Professor of Research Methodology at the University of Southampton and Director of the ESRC National Centre for Research Methods. He is Principal Investigator of the Wellcome Trust Monitor study and President of the European Survey Research Association. His main research interests are in the areas of survey and statistical methods, public opinion and political behaviour, particularly regarding social cohesion and trust and public attitudes to science and technology. Professor Andrew Tylecote Andrew Tylecote is Emeritus Professor of the Economics and Management of Technological Change at the University of Sheffield. His background extends across the social sciences, and his research has ranged widely around the broad question: how do social and economic institutions affect technological change and economic development? He has been Treasurer of the European Association for Evolutionary Political Economy, and Visiting Professor at Tsinghua and Zhejiang universities, China. He was joint winner of the Myrdal Prize for his book with Francesca Visintin on Corporate governance, finance, and the technological advantage of nations (Routledge, 2007). 187
Page 1 and 2:
Emerging b
Page 3:
Emerging b
Page 6 and 7:
Secretariat Hugh Whittall (Director
Page 9:
Foreword 1 The use of living organi
Page 13:
Terms of reference 1. To examine co
Page 16 and 17:
Applying public ethics: towards a p
Page 19 and 20:
E m e r g i n g b i o t e c h n o l
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29:
Page 32 and 33:
Page 35:
Part 1 Understanding emerging <stro
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 51 and 52:
Chapter 2 Biotechnology promises an
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Chapter 3 The threefold challenge o
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 105 and 106:
Chapter 5 Public perspectives
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Chapter 6 Research
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167: E m e r g i n g b i o t e c h n o l
Page 181 and 182: Chapter 9 Commercialisation
Page 203 and 204: Chapter 10 Conclusions: emerging <s
Page 209 and 210: Appendices
Page 215: E m e r g i n g b i o t e c h n o l
Page 239: Previous Nuffield
show all

Emerging biotechnologies: full report - Nuffield Council on Bioethics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?